CTOs on the Move

MicroDose Therapeutx

www.mdtx.com

 
MicroDose Therapeutx is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.mdtx.com
  • 4262 Us Highway 1 Ste 3
    Monmouth Junction, NJ USA 08852
  • Phone: 732.355.2100

Executives

Name Title Contact Details

Similar Companies

Xenotope Diagnostics

Xenotope Diagnostics is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Revolution Medicines

REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. We pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.

JPT Peptide Technologies GmbH

JPT Peptide Technologies GmbH is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MultiPlan

MultiPlan is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Triplet Therapeutics

Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington`s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.